Juvenile myelomonocytic leukemia is found in children as an aggressive pediatric myelodysplastic syndrome (MDS)/myeloproliferative disorder (MPD) symptomized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny . JMML constitutes approximately 30% of childhood cases of myelodysplastic syndrome and 2% of leukemia. JMML and CMML have a high frequency of mutations affecting the RAS signaling pathway and show hypersensitivity to stimulation with GM-CSF, which causes STAT5 hyperphosphorylation.
Juvenile myelomonocytic leukemia (JMML) is a rare childhood cancer that usually occurs in children younger than 2 years old. There are three main types of mutations found in Juvenile myelomonocytic leukemia which occur in a type of white cell known as a monocyte, which are a part of the body’s immune system, Juvenile myelomonocytic leukemia is a serious form of chronic leukaemia. Juvenile myelomonocytic leukemia accounts for less than 1% of all childhood leukaemias diagnosed. Cause of Juvenile myelomonocytic leukemia remains largely unknown. Allogeneic (donor) Stem Cell transplant is the only curative option for children with Juvenile myelomonocytic leukemia.
Related Journals of Juvenile Myelomonocytic Leukaemia